Syntaxis
Sinntaxis AB is a pre-revenue Swedish pharmaceutical company developing negative allosteric modulators of the mGluR5 receptor to enhance recovery of brain function after stroke, currently co-developing lead candidate dipraglurant with Addex Therapeutics.
- Company typePrivate
- Founded2017
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Syntaxis does
Sinntaxis AB is a privately held, pre-revenue Swedish pharmaceutical company founded in 2017 as a spin-off from Lund University, co-founded with LU Holding AB. The company is developing a single platform of negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 5 (mGluR5) to enhance recovery of sensory, motor, and cognitive brain functions after stroke — an indication where no approved drug therapy currently exists and where fewer than 10% of patients receive acute clot-removal treatment. Its preclinical evidence, published in the journal Brain under founder Prof. Tadeusz Wieloch, demonstrates that mGluR5 NAM treatment initiated up to 10 days post-stroke restores brain function through synaptic remodelling, with synergistic effects when combined with rehabilitation training.
The company's core asset is the mGluR5 NAM platform, and through a November 2023 option and collaboration agreement with Addex Therapeutics, Sinntaxis is co-developing dipraglurant, a phase II-ready mGlu5 NAM, as a lead drug candidate for brain injury recovery. Sinntaxis owns IP covering the use of mGluR5 NAMs for stroke recovery and operates from Lund, Sweden, within the SmiLe Incubator, with a team of 1–10 employees led by founder Tadeusz Wieloch (CEO), Chairman Christine Widstrand, and board member Lars Öhman.
Sinntaxis is pre-revenue and pre-commercial, with future revenue expected to flow from licensing royalties, co-development milestones, or eventual direct sales following regulatory approval of its drug candidates. Go-to-market will rely on licensing and co-development partnerships with larger pharmaceutical companies rather than internal sales infrastructure, given the asset-light, R&D-focused nature of the business. The addressable market is large — approximately 14 million stroke incidents globally each year and 27,000 in Sweden, with SEK 16 billion in annual societal costs in Sweden alone — but the company remains in preclinical-to-early-clinical development with a single therapeutic platform and a single lead candidate.
Syntaxis firmographics
Firmographics- Name
- Syntaxis
- Legal name
- Sinntaxis AB
- Website
- https://sinntaxis.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sinntaxis AB is a pre-revenue Swedish pharmaceutical company developing negative allosteric modulators of the mGluR5 receptor to enhance recovery of brain function after stroke, currently co-developing lead candidate dipraglurant with Addex Therapeutics.
- Ownership category
- akta.pro rank
Syntaxis industry classification
Industry- Product category
- Central Nervous System Pharmaceuticals
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Syntaxis is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Syntaxis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Drug Development: Pre-revenue pharmaceutical company developing novel therapeutics for stroke recovery. Revenue model will be through commercialization of drug candidates upon regulatory approval, likely through licensing agreements or direct pharmaceutical sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Syntaxis product offering
Product offeringCore offering
Sinntaxis is a preclinical-to-clinical stage pharmaceutical company developing novel therapeutics based on mGluR5 negative allosteric modulators (NAMs) to enhance recovery of brain functions after stroke. Its lead drug candidate, dipraglurant (a phase II ready mGlu5 NAM), is being co-developed with Addex Therapeutics under an option and collaboration agreement. The therapy restores brain function through synaptic remodeling and can be initiated up to 10 days after stroke onset, synergistically enhancing recovery when combined with rehabilitation training.
Product overview
Sinntaxis is a pharmaceutical company with a single core drug discovery platform focused on mGluR5 negative allosteric modulators (NAMs) for stroke recovery. The company is developing its lead drug candidate dipraglurant (a phase II ready mGlu5 NAM) in collaboration with Addex Therapeutics. The platform employs mGluR5 inhibitors to restore brain function after stroke through synaptic remodelling.
Differentiator
Problem solved
Functional benefit
Products and services
- mGluR5 Negative Allosteric Modulators (NAMs) Platform
- Dipraglurant (mGlu5 NAM)
Companies that use Syntaxis
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Syntaxis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Syntaxis partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Addex TherapeuticscoreOption and collaboration agreement to jointly advance the development of dipraglurant, a phase II ready mGlu5 negative allosteric modulator, as a potential treatment for patients with brain injuries. Combines Addex's platform and know-how in allosteric modulation with Sinntaxis's neuroscience/stroke research expertise.
- Lund UniversitycoreSinntaxis was founded by scientists at Lund University and LU Holding AB. Ongoing collaboration with Professor Tadeusz Wieloch's research group at the Laboratory for Experimental Brain Research.
Scale indicators3 records
Recent moves7 records
Expansion highlights4 records
Syntaxis competitors and assessment
Company assessmentDirect peers
- ReNeuron Group: UK-based cell therapy developer with a stroke disability program (CTX cells). Comparable as a small European clinical-stage biotech focused on post-stroke functional recovery.
- NoNO Inc. Biotech developing neuroprotective therapeutics for stroke and other CNS injuries. Directly comparable as a focused, clinical-stage stroke therapy company targeting post-stroke recovery and brain injury.
- DiaMedica Therapeutics: Clinical-stage biopharmaceutical company developing DM199 (recombinant KLK1) for acute ischemic stroke. Comparable as a small, focused stroke therapy developer with a single late-stage asset.
- Addex Therapeutics: Clinical-stage biopharmaceutical company and Sinntaxis's co-development partner. Both companies work on mGluR5 negative allosteric modulators (dipraglurant), making Addex the most directly comparable peer by target and mechanism.
- Athersys: Clinical-stage cell therapy company whose lead program MultiStem has been investigated for ischemic stroke. Comparable as a small-cap company pursuing novel post-stroke recovery modalities.
Broad incumbents
- CSL Behring: Large global biotherapeutics franchise with established neurology, hematology, and acute-care hospital products. Comparable as a broad incumbent in stroke-adjacent therapeutic areas and a likely eventual commercial partner or acquirer.
- Roche: Major pharmaceutical company with large neurology and stroke research investments and established CNS commercialization infrastructure. Comparable as a broad incumbent whose scale could license or acquire late-stage stroke recovery assets.
Others
- A1M Pharma: Swedish biotech previously led by Tomas Eriksson (Sinntaxis's former CEO). Thematically comparable as a small Nordic clinical-stage pharmaceutical company, though its focus (pre-eclampsia, acute kidney injury) differs from Sinntaxis's stroke recovery thesis.
Emerging players
- ZZ Biotech: Clinical-stage company developing 3K3A-APC, a recombinant protein being studied for acute ischemic stroke. Comparable as a focused, smaller-stroke-recovery therapeutics developer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Syntaxis social profiles
Digital presenceSyntaxis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Syntaxis leadership team
Management profileNumber of profiles
Profiles3 records
Syntaxis funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Syntaxis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Syntaxis
What does Syntaxis do?
Sinntaxis is a preclinical-to-clinical stage pharmaceutical company developing novel therapeutics based on mGluR5 negative allosteric modulators (NAMs) to enhance recovery of brain functions after stroke. Its lead drug candidate, dipraglurant (a phase II ready mGlu5 NAM), is being co-developed with Addex Therapeutics under an option and collaboration agreement. The therapy restores brain function through synaptic remodeling and can be initiated up to 10 days after stroke onset, synergistically enhancing recovery when combined with rehabilitation training.
Is Syntaxis a public or private company?
Syntaxis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Syntaxis founded?
Syntaxis was founded in 2017. It employs 1 to 10 people.
Where is Syntaxis based?
Syntaxis is headquartered in Lund, Sweden, in the Europe region.
How does Syntaxis make money?
One revenue line is on record: pharmaceutical Drug Development.
Who are Syntaxis's main competitors?
Direct peers on record are ReNeuron Group, NoNO Inc., DiaMedica Therapeutics, Addex Therapeutics and Athersys. Broad incumbents are CSL Behring and Roche. A1M Pharma is listed as an others. ZZ Biotech is listed as an emerging player.
Does Syntaxis have an API?
No public API is recorded for Syntaxis.
What industry is Syntaxis in?
Syntaxis's product category is Central Nervous System Pharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution).